Format

Send to

Choose Destination
Am J Addict. 2006 Jan-Feb;15(1):105-10.

Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals.

Author information

1
Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, South Carolina 29425, USA. larowe@musc.edu

Abstract

A double-blind placebo-controlled crossover Phase I trial was conducted to assess the safety and tolerability of N-Acetylcysteine (NAC) in healthy, cocaine-dependent humans. Thirteen participants attended a three-day hospitalization in which they received placebo or NAC. Subjects were crossed over to receive the opposite medication condition during a second three-day hospitalization, which occurred the following week. Across placebo and NAC conditions, only mild side effects were noted, and the number of subjects reporting side effects did not differ. There were trends for a greater reduction in withdrawal symptoms and craving within the NAC condition. These preliminary results suggest that NAC is well tolerated in healthy, cocaine-dependent individuals and may reduce cocaine-related withdrawal symptoms and craving.

PMID:
16449100
PMCID:
PMC1513138
DOI:
10.1080/10550490500419169
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center